Provided by Tiger Fintech (Singapore) Pte. Ltd.

Icosavax, Inc.

15.31
0.0000
Volume:- -
Turnover:142.68M
Market Cap:777.79M
PE:-6.98
High:15.31
Open:15.31
Low:15.31
Close:15.31
Loading ...

Company Profile

Company Name:
Icosavax, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.